Overview

* Syndax Q3 revenue grows 21% yr/yr but misses analyst expectations

* Adjusted EPS for Q3 beats consensus

* Company reports strong demand for Revuforj and Niktimvo, with significant revenue increases

Outlook

* Company expects full-year operating expenses of $380 to $385 mln

* Syndax anticipates stable operating expenses over the next few years

* Company projects cash reserves and revenue to lead to profitability

Result Drivers

* REVUFORJ DEMAND - Strong demand for Revuforj evidenced by 25% increase in prescriptions and 12% revenue growth over 2Q25

* FDA APPROVAL IMPACT - Recent FDA approval for Revuforj in R/R NPM1m AML boosts demand

* NIKTIMVO REVENUE GROWTH - Niktimvo net revenue increased by 27% over 2Q25, supported by co-commercialization with Incyte

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $45.87 $47.97

Revenue mln mln (14

Analysts

)

Q3 EPS Beat -$0.70 -$0.71

(13

Analysts

)

Q3 Net Beat -$60.71 -$61.84

Income mln mln (12

Analysts

)

Q3 Cash $456.10

& mln

Investme

nts

Q3 $103.29

Operatin mln

g

Expenses

Q3 -$57.42

Operatin mln

g Income

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Syndax Pharmaceuticals Inc ( SNDX ) is $37.50, about 63.5% above its October 31 closing price of $13.70

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)